Apnimed (APMD) vs Geron (GERN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Geron is the larger company by market cap ($767.8 million vs $734.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APMD | GERN |
|---|---|---|
| Share price | $17.63 | $1.20 |
| Market cap | $733.95M | $767.76M |
| 1-day change | -2.27% | -0.42% |
| YTD return | — | -9.09% |
| 1-year return | — | -6.98% |
| 5-year return | — | -14.89% |
| P/E ratio (TTM) | 2.44 | — |
| Forward P/E | — | 29.88 |
| EPS (TTM) | $7.22 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.29 | $2.01 |
| 52-week low | $16.12 | $1.04 |
| Distance from 52-week high | -50.04% | -40.55% |
| Analyst consensus | none | none |
| Avg. price target upside | +185.48% | +255.65% |
| Average volume | 556.65K | 10.09M |
| Shares outstanding | 41.63M | 642.47M |
| Employees | 81 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apnimed
APMD stock →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
APMD vs GERN FAQ
Which is bigger, Apnimed or Geron?
Geron (GERN) is larger, with a market capitalization of $767.76M compared with $733.95M for Apnimed (APMD).
Are Apnimed and Geron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.